证券代码：688221 证券简称：前沿生物 公告编号：2026-003 前沿生物药业（南京）股份有限公司2025年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 （二）业绩预告情况 1、经财务部门初步测算，预计2025年度实现营业收入约14,000.00万元到14,500.00万元，同比增加 8.13%到11.99%，营业收入主要来自抗HIV创新药艾可宁?（通用名：艾博韦泰）、代理产品缬康韦? （盐酸缬更昔洛韦）及报告期内获批的远红外治疗贴（小沿易贴?）的销售收入。 2、经财务部门初步测算，预计2025年度归属于上市公司股东的净利润亏损约25,500.00万元到亏损 29,000.00万元，增加亏损约5,361.74万元到8,861.74万元，主要系2024年度处置子公司股权产生7,183.65 万元的投资收益，2025年度无该类投资收益所致；预计2025年度归属于上市公司股东的扣除非经常性损 益的净利润亏损约28,800. ...

此外，2025年度，公司预计实现营业收入约1.4亿元到1.45亿元，同比增加8.13%到11.99%，营业收入主 要来自抗HIV创新药艾可宁（通用名：艾博韦泰）、代理产品缬康韦（盐酸缬更昔洛韦）及报告期获批 的远红外治疗贴（小沿易贴）的销售收入。 前沿生物表示，本次净利增亏主要系2024年度处置子公司股权产生7183.65万元的投资收益，2025年度 无该类投资收益所致。 北京商报讯（记者 丁宁）1月30日晚间，前沿生物（688221）发布2025年业绩预告显示，经财务部门初 步测算，预计2025年归属净利润约-2.55亿元到-2.9亿元，同比增亏。 ...

Core Insights - The report highlights the potential of small nucleic acid drugs in the weight loss market, focusing on two key targets: INHBE and ALK7, which are involved in fat metabolism regulation [5][11][12] - The UCO-SAF industry is experiencing tight supply and increasing prices due to high global demand and reduced overseas supply, with significant profit margins for SAF in China [6][17][18] - The company, Daotong Technology, is recognized as a global leader in digital repair, with strong growth prospects in its AI and robotics solutions, maintaining a "buy" rating [7][21][22] Industry Analysis - The small nucleic acid drug sector is positioned to address unmet clinical needs in weight management, with promising data from ongoing trials [12][13][14] - The SAF market is expected to grow rapidly due to increasing global demand and regulatory support, particularly in Europe and China, despite challenges in overseas supply [17][18] - The digital repair market is expanding, driven by regulatory requirements for TPMS installation and a growing vehicle population, with Daotong Technology poised to capitalize on this trend [21][24][25] Company Insights - Arrowhead and Wave are leading the development of small nucleic acid drugs, with upcoming trial data expected to provide insights into their efficacy and safety [12][14] - Frontline Bio is enhancing its competitive edge through a diversified pipeline that includes innovative drugs and high-end generics, with a focus on HIV treatment [8][27][28] - Daotong Technology's recent achievements in North America solidify its market leadership and open new opportunities in emerging markets [21][22][25]

Group 1 - The company, established in 2013 and listed on the Shanghai Stock Exchange in 2020, has developed a core self-researched HIV drug, Aikening (Aibowei Tai), which was approved in 2018, marking a significant milestone in its development [1] - The company is focusing on an innovative pipeline that combines innovative drugs and high-end generics, covering long-acting HIV drugs, small nucleic acid drugs, high-end generics, and medical devices, enhancing its core competitiveness [1] - The company anticipates steady growth in sales of HIV medications and potential growth from its small nucleic acid innovation pipeline, projecting net profits of -176 million, -171 million, and -164 million yuan for 2025-2027, with corresponding EPS of -0.47, -0.46, and -0.44 yuan, and a current PE ratio of -31.6, -32.6, and -33.8 times [1] Group 2 - The company is advancing in the small nucleic acid field, focusing on chronic disease treatment with self-researched ACORDE delivery carrier siRNA drugs, targeting diseases such as IgA nephropathy and dyslipidemia, with selected targets showing First-in-Class (FIC) or Best-in-Class (BIC) potential [2] - In the IgA nephropathy area, the company has three siRNA drugs targeting complement mechanisms, with FB7013 (single target MASP-2) expected to submit an IND application by the end of 2025, and FB7011 (dual targets MASP-2 and CFB) showing promising preclinical results [2] - The company has developed an innovative siRNA delivery carrier, ACORDE, and is exploring kidney and central nervous system delivery, which may further open growth opportunities [2] Group 3 - Aikening (injection form of Aibowei Tai) is the core product for long-acting HIV treatment, approved in 2018 as the first long-acting HIV fusion inhibitor globally, with potential for expanded market coverage and penetration into lower-tier markets [3] - The company is actively advancing the research and development of new long-acting HIV formulations and is assembling a complete long-acting treatment regimen [3] - The strategic layout of high-end generics and medical devices is expected to continuously contribute to the company's revenue growth [3]